Source comparison
MOTS-c vs Metformin: Overlapping and Distinct Pathways
Primary Mechanism AMPK activation via folate-methionine cycle disruption AMPK activation via mitochondrial Complex I inhibition MOTS-c activates AMPK without inhibiting ATP production. Metformin's mechanism involves transient energetic stress Insulin Sensitivi
This comparison does not assign a generated winner or score.
- Primary Mechanism
- AMPK activation via folate-methionine cycle disruption
- AMPK activation via mitochondrial Complex I inhibition
- MOTS-c activates AMPK without inhibiting ATP production. Metformin's mechanism involves transient energetic stress
- Insulin Sensitivity Effect
- Increased glucose uptake in muscle and adipose without hepatic glucose suppression
- Primarily hepatic glucose output reduction
- MOTS-c targets peripheral tissue insulin resistance; metformin targets hepatic overproduction
- Mitochondrial Biogenesis
- Direct upregulation of PGC-1α and mitochondrial gene expression
- Indirect upregulation through AMPK → PGC-1α pathway
- MOTS-c shows faster mitochondrial biogenesis response in animal models (detectable at 48 hours vs 7–10 days for metformin)
- GI Tolerability
- No reported GI adverse effects in preclinical models
- 20–30% of patients experience nausea, diarrhea, or abdominal discomfort
- MOTS-c bypasses gut-mediated mechanisms that cause metformin's GI side effects
- Half-Life
- Approximately 2.5 hours in circulation (mouse data)
- 4–6 hours
- MOTS-c requires more frequent dosing or sustained-release formulation for therapeutic use